COVID-19: Celltrion’s therapeutic optionIn just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. Share XCOVID-19: Celltrion’s therapeutic optionhttps://pharmaphorum.com/r-d/covid-19-providing-a-therapeutic-option/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
EMA finds possible link between mRNA COVID jabs and myocarditisThe EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based Share XEMA finds possible link between mRNA COVID jabs and myocarditishttps://pharmaphorum.com/news/ema-backs-link-between-mrna-covid-jabs-and-myocarditis/
EU okays BMS’ azacitidine pill for first-line maintenance of AMLBristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that Share XEU okays BMS’ azacitidine pill for first-line maintenance of AMLhttps://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/
J&J must ditch 60m COVID jabs made at US plant, but 10m are okay, says FDAThe failings at a Baltimore, US factory making Johnson & Johnson’s COVID-19 vaccine mean that millions of doses Share XJ&J must ditch 60m COVID jabs made at US plant, but 10m are okay, says FDAhttps://pharmaphorum.com/news/jj-must-ditch-60m-covid-jabs-made-at-us-plant-but-10m-are-okay-says-fda/
How will NICE fare in a post-Brexit world?NICE has a global reputation as a pioneering HTA – but is that influence at risk now that Share XHow will NICE fare in a post-Brexit world?https://deep-dive.pharmaphorum.com/magazine/market-access-2021/nice-post-brexit-icon/
EU starts rolling review of GSK’s antibody for COVID-19The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which Share XEU starts rolling review of GSK’s antibody for COVID-19https://pharmaphorum.com/news/eu-starts-rolling-review-of-gsks-antibody-for-covid-19/
Calliditas eyes 2022 approval in EU for rare kidney disease drug NefeconCalliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), Share XCalliditas eyes 2022 approval in EU for rare kidney disease drug Nefeconhttps://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/
EMA starts review of GSK/Vir COVID-19 antibodyThe EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which Share XEMA starts review of GSK/Vir COVID-19 antibodyhttps://pharmaphorum.com/news/ema-starts-review-of-gsk-vir-covid-19-antibody/
